[go: up one dir, main page]

MX2018002121A - Elaboracion de fosfatasas alcalinas. - Google Patents

Elaboracion de fosfatasas alcalinas.

Info

Publication number
MX2018002121A
MX2018002121A MX2018002121A MX2018002121A MX2018002121A MX 2018002121 A MX2018002121 A MX 2018002121A MX 2018002121 A MX2018002121 A MX 2018002121A MX 2018002121 A MX2018002121 A MX 2018002121A MX 2018002121 A MX2018002121 A MX 2018002121A
Authority
MX
Mexico
Prior art keywords
culture medium
zinc
manufacturing
alkaline phosphatases
concentration
Prior art date
Application number
MX2018002121A
Other languages
English (en)
Inventor
Jaluria Pratik
SUI Siguang
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2018002121A publication Critical patent/MX2018002121A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para producir un polipéptido recombinante, que comprende: (a) proporcionar un biorreactor con alimentación por lotes de 100 L a 25,000 L que comprende (i) células capaces de expresar el polipéptido recombinante de asfotasa alfa (sec. con núm. de ident.: 1), y (ii) un medio de cultivo adecuado para llevar a cabo dicha expresión, el medio de cultivo comprende de aproximadamente 25 µM a aproximadamente 300 µM de zinc; (b) cultivar las células en condiciones adecuadas para expresar la asfotasa alfa recombinante; en donde el pH del medio de cultivo es de aproximadamente 6.7 a aproximadamente 7.1, y en donde se adiciona zinc a dicho medio de cultivo de manera que la concentración de zinc en el medio de cultivo se mantenga a una concentración de aproximadamente 25 µM a aproximadamente 300 µM de zinc.
MX2018002121A 2015-08-17 2016-08-16 Elaboracion de fosfatasas alcalinas. MX2018002121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206001P 2015-08-17 2015-08-17
PCT/US2016/047166 WO2017031114A1 (en) 2015-08-17 2016-08-16 Manufacturing of alkaline phosphatases

Publications (1)

Publication Number Publication Date
MX2018002121A true MX2018002121A (es) 2018-06-18

Family

ID=56851690

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002121A MX2018002121A (es) 2015-08-17 2016-08-16 Elaboracion de fosfatasas alcalinas.

Country Status (12)

Country Link
US (1) US11352612B2 (es)
EP (1) EP3337894A1 (es)
JP (1) JP6993961B2 (es)
KR (1) KR102644116B1 (es)
CN (1) CN108350440A (es)
AU (1) AU2016308624B2 (es)
CA (1) CA2993358A1 (es)
CO (1) CO2018001450A2 (es)
HK (1) HK1257341A1 (es)
MX (1) MX2018002121A (es)
RU (1) RU2745528C2 (es)
WO (1) WO2017031114A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP3592372A4 (en) * 2017-03-09 2021-01-13 Alexion Pharmaceuticals, Inc. GLYCOPROTEIN MANUFACTURING PROCESS
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
US20200121767A1 (en) * 2017-04-13 2020-04-23 Alexion Pharmaceuticals, Inc. Methods for identifying the health state of hypophosphatasia (hpp) patients
AU2019207600B2 (en) 2018-01-09 2025-01-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
HUE069711T2 (hu) * 2018-03-16 2025-04-28 Genzyme Corp Eljárások sejt életképességének javítására termelõ bioreaktorban
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
CA3093853A1 (en) 2018-03-26 2019-10-03 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
JP2021519590A (ja) * 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
US20210189358A1 (en) * 2018-06-18 2021-06-24 Synthetic Biologics, Inc. Methods of making alkaline phosphatase agents
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3859009A4 (en) * 2018-09-25 2022-08-10 Toray Industries, Inc. METHODS TO EVALUATE THE QUALITY OF A DEPHOSPHORYLATION REAGENT AND METHODS TO DETECT A TARGET NUCLEIC ACID
US12318434B2 (en) 2019-05-06 2025-06-03 Theriva Biologics, Inc. Alkaline phosphate-based oncology treatments
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2021138581A1 (en) 2020-01-03 2021-07-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tnap locally administered for promoting periodontal health
JP7510787B2 (ja) 2020-05-28 2024-07-04 シスメックス株式会社 アルカリフォスファターゼ融合抗体及びその製造方法、並びに免疫測定用試薬及び免疫測定方法
US20230313259A1 (en) * 2020-08-14 2023-10-05 Bristol-Myers Squibb Company Manufacturing process for protein
JP2023538881A (ja) * 2020-08-14 2023-09-12 ブリストル－マイヤーズ スクイブ カンパニー タンパク質の製造方法
JP2023546682A (ja) * 2020-10-23 2023-11-07 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造中に総シアル酸含量（ｔｓａｃ）を制御する方法
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DK0478797T3 (da) 1990-04-20 1995-06-26 Hisayuki Matsuo Nyt fysiologisk aktivt peptid stammende fra gris
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP2977158B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）
JP2977159B2 (ja) 1990-09-07 1999-11-10 壽之 松尾 カエル由来新規生理活性ペプチド（カエルｃｎｐ）
JP3026352B2 (ja) 1990-09-11 2000-03-27 壽之 松尾 ラットＣＮＰｃＤＮＡ及び前駆体蛋白
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
WO1992020371A1 (en) 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
AU4835693A (en) 1993-08-13 1995-03-14 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5665704A (en) 1993-11-12 1997-09-09 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
WO1995013296A1 (en) 1993-11-12 1995-05-18 Genentech, Inc. Receptor specific atrial natriuretic peptides
EP0763061B1 (de) 1994-06-02 2002-10-30 Forssmann, Wolf-Georg, Prof. Dr. med. Verfahren zur herstellung von cardiodilatin-fragmenten, hochgereinigte cardiodilatin-fragmente und zwischenprodukte zu deren herstellung
JPH0870875A (ja) 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
ZA979060B (en) 1996-10-22 1999-04-09 Genentech Inc Receptor selective BNP
US6455495B1 (en) 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CA2245903A1 (en) 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
CA2260376A1 (en) 1999-02-11 2000-08-11 Universite De Montreal New metalloproteases of the neprilysin family
CA2262056A1 (en) 1999-02-24 2000-08-24 Guy Boileau Composition, methods and reagents for the synthesis of a soluble form of human pex
AU2495200A (en) 1999-03-08 2000-09-28 Genentech Inc. Compositions and methods for the treatment of tumor
CA2369999A1 (en) 1999-04-28 2000-11-02 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP4217004B2 (ja) 1999-05-17 2009-01-28 コンジュケム バイオテクノロジーズ インコーポレイテッド 血液成分への結合体化を介するペプチダーゼ活性からの内因性治療用ペプチドの保護
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
DE19942230C2 (de) 1999-09-03 2003-09-25 Wolf-Georg Forssmann Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
EP1232276B8 (en) 1999-11-16 2007-06-27 Genzyme Corporation Vectors and transgenes with regulatory elements for gene delivery to the liver
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
AU2583901A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
JP4237375B2 (ja) 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
EP1502604A1 (en) 2000-04-26 2005-02-02 Cellegy Pharmaceuticals, Inc Use of nitric oxide mimetics in cancer treatment
ATE281177T1 (de) 2000-04-26 2004-11-15 Cellegy Pharma Inc Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp
US20050142217A1 (en) 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6830885B1 (en) 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
ATE341631T1 (de) 2000-08-23 2006-10-15 Enobia Pharma Inc Methode und zusammensetzung zur förderung von osteogenese
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
JP2002178279A (ja) 2000-12-12 2002-06-25 Ulvac Japan Ltd 基板搬送方法
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP2002246704A (ja) 2001-02-16 2002-08-30 Philips Japan Ltd 電子装置及び回路装置
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20020183276A1 (en) 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
IL159857A0 (en) 2001-07-16 2004-06-20 Hk Pharmaceuticals Inc Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US20050202442A1 (en) 2003-12-15 2005-09-15 Morris David W. Novel therapeutic targets in cancer
CA2469972A1 (en) 2001-12-20 2003-07-03 Phenogene Therapeutiques Inc. Bone polypeptide-1
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20030158132A1 (en) 2002-01-22 2003-08-21 Genvec, Inc. Method for enhancing bone density or formation
EP1492567A1 (en) 2002-03-06 2005-01-05 Cellegy Pharmaceuticals, Inc Formulations and methods of using nitric oxide mimetics in cancer treatment
AU2003214214A1 (en) 2002-03-18 2003-10-08 Scios Inc. Method for treating congestive heart failure
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
CA2488348A1 (en) 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
WO2004022579A2 (en) 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
AU2003302087A1 (en) 2002-11-18 2004-06-15 Syn X Pharma, Inc. Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1572645A2 (en) 2002-12-03 2005-09-14 Enobia Pharma Inc. Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
EP1583554A2 (en) 2003-01-13 2005-10-12 Gudrun Rappold-Hoerbrand Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
JP2009520459A (ja) 2003-02-14 2009-05-28 サイグレス ディスカバリー， インコーポレイテッド 癌における治療標的
US7488713B2 (en) 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
EP1616181B1 (en) 2003-04-17 2009-08-12 Vermillion, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use
WO2005007809A2 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
DK1644740T3 (da) 2003-06-17 2011-02-21 Otago Innovation Ltd Vurdering af skeletal vækst ved anvendelse af målinger af NT-CNP-peptider
EP2308889B1 (en) 2003-06-20 2018-05-23 Mayo Foundation For Medical Education And Research Isoforms of brain natriuretic peptide
WO2005052593A1 (en) 2003-10-29 2005-06-09 The University Of Leicester Detection
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
AU2005207886A1 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
US20080182299A1 (en) 2004-01-27 2008-07-31 Compugent Ltd. Novel brain natriuretic peptide variants and methods of use thereof
CA2558911C (en) 2004-03-11 2016-12-06 Genentech, Inc. Process for producing polypeptides
KR20070007842A (ko) 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
AU2005228817B2 (en) 2004-03-31 2011-06-16 Chugai Seiyaku Kabushiki Kaisha Remedy or preventive for arthritis
JP2005292718A (ja) 2004-04-05 2005-10-20 Furukawa Electric Co Ltd:The 光導波路、光導波路モジュールおよび光導波路の作成方法
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
AU2005244061A1 (en) 2004-05-10 2005-11-24 Novacea, Inc. Prevention of arterial restenosis with active vitamin D compounds
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US20070081986A1 (en) 2005-10-07 2007-04-12 Shunji Tomatsu Beta-glucuronidase with an attached short peptide of acidic amino acids
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
ATE496060T1 (de) 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
MX2007006524A (es) 2004-12-01 2007-06-22 Genzyme Corp Metodos para el suministro dirigido de material genetico al higado.
PT2510942E (pt) 2005-04-07 2015-12-28 Cardiorentis Ag Utilização de péptido natriurético para o tratamento de insuficiência cardíaca
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
US20070042957A1 (en) 2005-08-19 2007-02-22 Mayo Foundation For Medical Education And Research Type v phosphodiesterase inhibitors and natriuretic polypeptides
US7470668B2 (en) 2005-08-24 2008-12-30 Enobia Pharma Inc. Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
AU2006343306A1 (en) 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Parathyroid hormone analogues and methods of use
WO2007035600A2 (en) 2005-09-16 2007-03-29 Mayo Foundation For Education And Research Natriuretic activities
WO2007041645A2 (en) 2005-10-03 2007-04-12 Scios Inc. Oxidized human bnp
RU2316334C2 (ru) 2005-12-19 2008-02-10 Медитек Индастриз ЛЛС Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
DK1987178T3 (en) 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
US8784833B2 (en) 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
JP2010501026A (ja) 2006-06-30 2010-01-14 インターフェース バイオロジクス，インコーポレーテッド 生体応答性ポリマー
CN101501067B (zh) 2006-08-08 2013-01-16 梅约医学教育与研究基金会 利尿和利尿钠的多肽
US7825092B2 (en) 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
MX2009002523A (es) 2006-09-08 2009-03-20 Ambrx Inc Polipeptido de plasma humano modificado o andamios fc y sus usos.
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
US7803769B2 (en) 2006-10-25 2010-09-28 Amgen Inc. OSK1 peptide analogs and pharmaceutical compositions
US20100168443A1 (en) 2006-11-02 2010-07-01 University Of Virginia Patent Foundation Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
US8987200B2 (en) 2006-11-16 2015-03-24 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
US20080181903A1 (en) 2006-12-21 2008-07-31 Pdl Biopharma, Inc. Conjugate of natriuretic peptide and antibody constant region
CA2680537C (en) 2007-03-12 2018-10-16 Soheyl Bahrami Diagnosis of septic complications
EP1985697A1 (en) * 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
EP2158319B1 (en) 2007-05-11 2011-12-07 Enobia Pharma Inc. Bone targeted alkaline phosphatase, kits and methods of use thereof
US20090252729A1 (en) 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
CA2689492A1 (en) 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
WO2009006520A1 (en) 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
WO2009006732A1 (en) 2007-07-06 2009-01-15 Theratechnologies Inc. Bifunctional fusion proteins of the alpha-melanocyte stimulating hormone (alpha-msh) and atrial natriuretic protein (anp) and uses in hypertension and acute kidney injury
EP2171053B1 (en) 2007-07-20 2014-04-23 Mayo Foundation for Medical Education and Research Natriuretic polypeptides
EP2190466A4 (en) 2007-08-10 2011-12-21 Burnham Inst Medical Research Tissue-specific alkaline phosphatase (TNAP) activators and their use
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009039982A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2187914A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Astressin and beta-endorphin for use as therapeutic agents
EP2185183B1 (en) 2007-09-11 2016-03-16 Cardiopep Pharma GmbH Use of natriuretic peptides for treating angioedema syndromes
RU2010113972A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение cnp-22 отдельно или в сочетании с физалемином в качестве терапевтического средства
EP2187951A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
JP2010539068A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｂ型ナトリウム利尿ペプチドおよびヒト成長ホルモン１−４３の治療的使用
US8357656B2 (en) 2007-09-15 2013-01-22 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-C agonists
AU2008326327A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
DK2277890T3 (en) 2008-05-23 2016-02-08 Daiichi Sankyo Co Ltd Peptide which is able to extend the half-life of a peptide of interest in the plasma
US20110152194A1 (en) 2008-06-06 2011-06-23 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
US20100008918A1 (en) 2008-06-26 2010-01-14 Acceleron Pharma Inc. Methods for dosing an actriib antagonist and monitoring of treated patients
EP2307447B1 (en) 2008-07-02 2016-03-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides with unique pharmacologic profiles
CN102112493B (zh) 2008-07-23 2015-04-01 韩美科学株式会社 包含具有三个官能性末端的非肽基聚合物的多肽复合物
US20100093678A1 (en) 2008-10-10 2010-04-15 The University Of Georgia Research Foundation, Inc Compositions and methods of the treatment of obesity and osteoporosis
US8642550B2 (en) 2008-10-24 2014-02-04 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides without hypotensive inducing capability
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
TW201031752A (en) 2009-01-19 2010-09-01 Hanmi Pharm Ind Co Ltd Method for producing physiologically active protein or peptide using immunoglobulin fragment
US20120093814A1 (en) 2009-03-30 2012-04-19 Boehringer Ingelheim International Gmbh Fusion Proteins Comprising Canine FC Portions
US20120053123A1 (en) 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
BR122019026832B1 (pt) 2009-05-20 2021-08-24 Biomarin Pharmaceutical Inc Variantes de peptídeo natriurético tipo c (cnp), seu método de produção recombinante e seu uso, composição farmacêutica, composição para tratamento de uma condição ou distúrbio responsivo a cnp e célula hospedeira para produção in vitro de um peptídeo cnp
US8685024B2 (en) 2010-04-14 2014-04-01 Arrowhead Medical Device Technologies, Llc Intramedullary fixation device and methods for bone fixation and stabilization
EA201291138A1 (ru) 2010-04-30 2013-05-30 Алексион Фарма Интернэшнл Сарл Способы, композиции и наборы для лечения нарушений, связанных с минерализацией матрикса
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
HK1202086A1 (en) 2011-11-10 2015-09-18 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014016585A1 (en) 2012-07-25 2014-01-30 Psioxus Therapeutics Limited Use of s-pindolol for treating cachexia and sarcopenia
US20160097100A1 (en) 2013-05-17 2016-04-07 Jeffrey Trent Genetic test to predict patient response to bone morphogenetic protein in arthrodesis
US10570380B2 (en) 2014-01-24 2020-02-25 Am-Pharma B.V. Downstream processing of an alkaline phosphatase
CN111778228A (zh) 2014-01-24 2020-10-16 安-法玛公司 嵌合型碱性磷酸酶样蛋白
SI3845245T1 (sl) 2014-06-09 2025-10-30 Ultragenyx Pharmaceutical Inc. Uspešen in učinkovit nadzor serumskega fosfata za optimalno tvorbo kosti
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
EP3207132B1 (en) 2014-10-15 2019-07-31 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
KR101867134B1 (ko) * 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017171871A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia

Also Published As

Publication number Publication date
RU2018109368A3 (es) 2020-02-10
CO2018001450A2 (es) 2018-04-30
EP3337894A1 (en) 2018-06-27
US11352612B2 (en) 2022-06-07
AU2016308624A1 (en) 2018-02-15
HK1257341A1 (zh) 2019-10-18
RU2020131552A (ru) 2020-10-20
JP2018523481A (ja) 2018-08-23
CA2993358A1 (en) 2017-02-23
US20180230445A1 (en) 2018-08-16
RU2745528C2 (ru) 2021-03-26
BR112018003214A2 (pt) 2018-09-25
AU2016308624B2 (en) 2022-06-23
CN108350440A (zh) 2018-07-31
WO2017031114A1 (en) 2017-02-23
RU2018109368A (ru) 2019-09-19
JP6993961B2 (ja) 2022-01-14
KR102644116B1 (ko) 2024-03-05
KR20180040590A (ko) 2018-04-20

Similar Documents

Publication Publication Date Title
MX2018002121A (es) Elaboracion de fosfatasas alcalinas.
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
EP4148121A3 (en) Cell-controlled perfusion in continuous culture
MX2021005715A (es) Derivacion sin alimentadores de celulas madre pluripotentes inducidas humanas con arn mensajero sintetico.
MX376623B (es) Cultivo celular metabolicamente optimizado.
WO2019014310A8 (en) Biological methods for preparing terpenes
NZ605403A (en) Method of producing recombinant adamts13 in cell culture
NZ797997A (en) Clostridium histolyticum enzymes and methods for the use thereof
MX2018002705A (es) Cepas de levadura para la expresion y secrecion de proteinas heterologas a altas temperaturas.
AR092588A1 (es) Metodo de obtencion de 1-kestosa
SG195299A1 (en) Expansion of stem cells in hollow fiber bioreactors
MX2016010236A (es) Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
MX338560B (es) Enzimas de fusion que tienen actividad de n-acetilglucosaminil transferasa.
EP4446338A3 (en) Cells and method of cell culture
BR112016012229A2 (pt) métodos de produção de polipeptídeos
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
MY180352A (en) Recombinant methanotrophic bacterium and a method of production of succinic acid from methane or biogas thereof
AR086200A1 (es) Hongos filamentosos que tienen un fenotipo de viscosidad alterado
MY194223A (en) Method and microorganism for methionine production by fermentation with improved methionine efflux
MX2022003016A (es) Metodo de produccion con iones de cobre controlados.
NZ595833A (en) Method of producing a lipolytic enzyme
WO2009080299A8 (en) Sm-protein based secretion engineering
NZ748634A (en) Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide
SG11201806843UA (en) Method for producing activated hepatocyte growth factor (hgf)